NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...

We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price traded down 4% during trading on Thursday after ...

We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...

Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.

Wednesday’s 10 Top Performers. In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne ...

Sarepta Therapeutics (SRPT) stock drops 25% as the company reports a patient death linked to Elevidys, its gene therapy developed with Roche (RHHBY). Read more here.

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know. Sarepta Therapeutics beat analysts’ revenue expectations by ...